Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03551249|
Recruitment Status : Active, not recruiting
First Posted : June 11, 2018
Last Update Posted : September 10, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Glioma Glioblastoma||Device: Focused ultrasound (FUS)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of High Grade Glioma in Patients Undergoing Standard Chemotherapy|
|Actual Study Start Date :||March 26, 2019|
|Estimated Primary Completion Date :||December 2023|
|Estimated Study Completion Date :||December 2024|
Experimental: Focused Ultrasound (FUS)
The ExAblate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing initial standard of care chemotherapy.
Device: Focused ultrasound (FUS)
FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
Other Name: ExAblate, Type 2
- Device and procedure related adverse events [ Time Frame: Throughout the study, approximately 12 months. ]The number and severity of device and BBB disruption procedure related adverse events will be evaluated and classified according to the CTCAE
- Feasibility of repeated BBB disruption will be evaluated through assessment of post-procedure contrast-enhanced magnetic resonance (MR) imaging [ Time Frame: At the time of each ExAblate MRgFUS procedure ]The repeatability of BBB disruption will be evaluated at each of the 6 procedures and will be evaluated through assessment of post-procedure contrast-enhanced MR imaging.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 80 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patient is eligible for adjuvant temozolomide (TMZ) treatment based on the current standard of care.
- Men or women age between 18 and 80 years, inclusive.
- Able and willing to give informed consent.
- Grade IV glioma (GBM)
- Combined radiation/TMZ treatment is completed based on the prescribed standard of care regimen.
- Karnofsky rating 70-100.
- Able to communicate during the ExAblate BBBD (Blood Brain Barrier Disruption) procedure.
- Able to attend all study visits (i.e., life expectancy of at least 3 months).
Patients presenting with the following imaging characteristics:
i. Evidence of acute intracranial hemorrhage.
The sonication pathway to the tumor involves:
i. Extensive scalp sores. ii. Clips or other metallic implanted objects in the skull or the brain (brain implants)
- The subject presents with symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, and papilledema).
- Patients with cerebellar or brainstem tumors.
- Patients with positive HIV status.
- Significant depression not adequately controlled with medication and at potential risk of suicide.
- Patient receiving bevacizumab (Avastin) therapy.
- Patients receiving treatment with corticosteroid doses greater than dexamethasone 24 mg daily (or equivalent).
- Patients undergoing other concurrent therapies such as chemotherapy wafers, immunotoxins delivered by convection-enhanced delivery, regionally administered gene and viral therapies, immunotherapies, focal irradiation with brachytherapy, stereotactic radiosurgery, laser interstitial thermotherapy, and tumor treatment fields therapy.
Cardiac disease or unstable hemodynamics including:
i. Documented myocardial infarction within six months of enrollment. ii. Unstable angina on medication. iii. Congestive heart failure. iv. Left ventricular ejection fraction <50%. v. History of a hemodynamically unstable cardiac arrhythmia. vi. Cardiac pacemaker.
- Severe hypertension (diastolic BP > 100 on medication).
- Anti-coagulant therapy, or medications known to increase risk of hemorrhage within washout period prior to treatment.
- History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor hemorrhage.
- Cerebral or systemic vasculopathy, including intracranial thrombosis, vascular malformation, cerebral aneurysm or vasculitis.
- History of drug or alcohol use disorder.
- Active seizure disorder or epilepsy (seizures despite medical treatment).
- Known sensitivity to gadolinium-based contrast agents.
- Known sensitivity to DEFINITY® ultrasound contrast agent or perflutren.
- Contraindications to MRI such as non-MRI-compatible implanted devices.
- Large subjects not fitting comfortably into the MRI scanner.
- Difficulty lying supine and still for up to 4 hours in the MRI unit or claustrophobia.
- Positive pregnancy test (women of childbearing potential).
- Severely impaired renal function or on dialysis.
- Cardiac shunt.
- Subjects with evidence of cranial or systemic infection.
- Subjects with significant liver dysfunction, e.g., history of cirrhosis or active hepatitis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03551249
|United States, Maryland|
|University of Maryland|
|Baltimore, Maryland, United States, 21201|
|United States, Massachusetts|
|Brigham and Women's Hospital|
|Boston, Massachusetts, United States, 02115|
|United States, Virginia|
|University of Virginia|
|Charlottesville, Virginia, United States, 22908|
|United States, West Virginia|
|West Virginia University|
|Morgantown, West Virginia, United States, 26506|
|Principal Investigator:||Graeme Woodworth, MD||University of Maryland|
|Other Study ID Numbers:||
|First Posted:||June 11, 2018 Key Record Dates|
|Last Update Posted:||September 10, 2022|
|Last Verified:||September 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
|Device Product Not Approved or Cleared by U.S. FDA:||Yes|
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue